Annual CFF
$231.94 M
+$116.19 M+100.39%
December 31, 2023
Summary
- As of February 22, 2025, NMRA annual cash flow from financing activities is $231.94 million, with the most recent change of +$116.19 million (+100.39%) on December 31, 2023.
- During the last 3 years, NMRA annual CFF has risen by +$1.84 million (+0.80%).
- NMRA annual CFF is now -20.98% below its all-time high of $293.51 million, reached on December 31, 2021.
Performance
NMRA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$1.53 M
-$1.12 M-42.31%
September 30, 2024
Summary
- As of February 22, 2025, NMRA quarterly cash flow from financing activities is $1.53 million, with the most recent change of -$1.12 million (-42.31%) on September 30, 2024.
- Over the past year, NMRA quarterly CFF has dropped by -$314.00 thousand (-17.02%).
- NMRA quarterly CFF is now -99.48% below its all-time high of $291.99 million, reached on September 1, 2021.
Performance
NMRA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$5.55 M
-$230.49 M-97.65%
September 30, 2024
Summary
- As of February 22, 2025, NMRA TTM cash flow from financing activities is $5.55 million, with the most recent change of -$230.49 million (-97.65%) on September 30, 2024.
- Over the past year, NMRA TTM CFF has dropped by -$228.13 million (-97.63%).
- NMRA TTM CFF is now -98.11% below its all-time high of $293.87 million, reached on September 1, 2021.
Performance
NMRA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
NMRA Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +100.4% | -17.0% | -97.6% |
| 3 y3 years | +0.8% | -26.5% | -98.1% |
| 5 y5 years | - | -26.5% | -98.1% |
NMRA Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -21.0% | +100.4% | -99.3% | +418.3% | -98.1% | at low |
| 5 y | 5-year | -21.0% | +100.4% | -99.5% | +418.3% | -98.1% | +347.5% |
| alltime | all time | -21.0% | +100.4% | -99.5% | +418.3% | -98.1% | +347.5% |
Neumora Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $1.53 M(-42.3%) | $5.55 M(-97.6%) |
| Jun 2024 | - | $2.65 M(+43.8%) | $236.04 M(+1.0%) |
| Mar 2024 | - | $1.84 M(-483.6%) | $233.68 M(+0.8%) |
| Dec 2023 | $231.94 M(+100.4%) | -$481.00 K(-100.2%) | $231.94 M(-10.5%) |
| Sep 2023 | - | $232.02 M(>+9900.0%) | $259.25 M(+126.6%) |
| Jun 2023 | - | $292.00 K(+189.1%) | $114.40 M(-1.5%) |
| Mar 2023 | - | $101.00 K(-99.6%) | $116.19 M(+0.4%) |
| Dec 2022 | $115.74 M | $26.83 M(-69.2%) | $115.74 M(+30.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | $87.18 M(+4085.2%) | $88.55 M(-69.8%) |
| Jun 2022 | - | $2.08 M(-693.4%) | $293.36 M(+0.5%) |
| Mar 2022 | - | -$351.00 K(-2.0%) | $291.92 M(-0.5%) |
| Dec 2021 | $293.51 M(+27.6%) | - | - |
| Dec 2021 | - | -$358.00 K(-100.1%) | $293.51 M(-0.1%) |
| Sep 2021 | - | $291.99 M(>+9900.0%) | $293.87 M(>+9900.0%) |
| Jun 2021 | - | $640.00 K(-48.4%) | $1.88 M(+51.6%) |
| Mar 2021 | - | $1.24 M | $1.24 M |
| Dec 2020 | $230.10 M | - | - |
FAQ
- What is Neumora Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Neumora Therapeutics?
- What is Neumora Therapeutics annual CFF year-on-year change?
- What is Neumora Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Neumora Therapeutics?
- What is Neumora Therapeutics quarterly CFF year-on-year change?
- What is Neumora Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Neumora Therapeutics?
- What is Neumora Therapeutics TTM CFF year-on-year change?
What is Neumora Therapeutics annual cash flow from financing activities?
The current annual CFF of NMRA is $231.94 M
What is the all time high annual CFF for Neumora Therapeutics?
Neumora Therapeutics all-time high annual cash flow from financing activities is $293.51 M
What is Neumora Therapeutics annual CFF year-on-year change?
Over the past year, NMRA annual cash flow from financing activities has changed by +$116.19 M (+100.39%)
What is Neumora Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of NMRA is $1.53 M
What is the all time high quarterly CFF for Neumora Therapeutics?
Neumora Therapeutics all-time high quarterly cash flow from financing activities is $291.99 M
What is Neumora Therapeutics quarterly CFF year-on-year change?
Over the past year, NMRA quarterly cash flow from financing activities has changed by -$314.00 K (-17.02%)
What is Neumora Therapeutics TTM cash flow from financing activities?
The current TTM CFF of NMRA is $5.55 M
What is the all time high TTM CFF for Neumora Therapeutics?
Neumora Therapeutics all-time high TTM cash flow from financing activities is $293.87 M
What is Neumora Therapeutics TTM CFF year-on-year change?
Over the past year, NMRA TTM cash flow from financing activities has changed by -$228.13 M (-97.63%)